Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus WESTCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus WESTCORT.
CAPEX vs WESTCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply a thin film to affected area twice daily. Use for no longer than 2 consecutive weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life is 2-4 hours. Clinical context: Requires multiple daily applications for sustained effect; systemic accumulation unlikely with topical use.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily renal (70-90% as metabolites, <5% unchanged); minor biliary/fecal (10-20%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid